Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7381 to 7395 of 7687 results

  1. Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

    Discontinued [GID-TA10750]

    Technology appraisal guidance
    Discontinued

  2. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development [GID-TA10758] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development [GID-TA11482] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]

    In development [GID-TA11580] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Technology appraisal guidance
    Published
    27 July 2016

  6. Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]

    In development [GID-TA11475] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development [GID-TA11301] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065

    In development [GID-TA11588] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development [GID-TA10826] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development [GID-TA11044] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued [GID-TA11396]

    Technology appraisal guidance
    Discontinued

  12. Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

    This advice has been replaced by NICE diagnostics guidance 37.

    Medtech innovation briefing
    Published
    18 January 2018

  13. PICO negative pressure wound therapy for closed surgical incision wounds (MIB149)

    This advice has been updated and replaced by NICE medical technologies guidance 43.

    Medtech innovation briefing
    Published
    15 June 2018

  14. QAngio XA 3D/QFR imaging software for assessing coronary obstructions (MIB146)

    This advice has been updated and replaced by NICE diagnostics guidance 43.

    Medtech innovation briefing
    Published
    15 May 2018

  15. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

    This medtech innovation briefing (MIB) has been updated and replaced by NICE diagnostics guidance 41.

    Medtech innovation briefing
    Published
    16 February 2018